Latest news

• Expert review shows AstraZeneca’s COVID-19 vaccine is ‘equally effective’ as mRNA vaccines

  AstraZeneca’s (AZ) COVID-19 vaccine, Vaxzevria, and the available mRNA COVID-19 vaccines provide ‘equally effective’ protection against hospitalisation and death, an expert review of data from 79 real-world ... Our expert review shows that

• AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster

  Vaxzevria, following a primary vaccine schedule of either Vaxzevria or an mRNA COVID-19 vaccine. ... Vaxzevria is known as a ‘viral vector’ vaccine, which uses a form of a virus that cannot cause disease to create the vaccine.

• AstraZeneca’s Vaxzevria trial provides further support for protection against COVID-19 variants

  Results from the trial involved individuals who had previously been vaccinated with either an mRNA vaccine or Vaxzevria. ... So far, Vaxzevria has been granted emergency use approval and conditional marketing authorisation in more than 90 countries.

• Mix-and-match COVID-19 vaccines may be more effective

  responses’ following an initial course of the Oxford/AstraZeneca vaccine, sold under the name Covishield or Vaxzevria.

• GSK/SK bioscience COVID-19 vaccine to enter phase 3 trial

  testing of its COVID-19 vaccine candidate against AstraZeneca’s Vaxzevria.